comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists It's important to study the difference in medications. Our analysis found is associated a lower risk of serious heart complications compared to dulaglutide in adults with Type Cardiovascular, Kidney, and Safety Outcomes
Description
Ethics declarations Ethics approval and consent to participate The study was approved by the ethics committee of the Medical University Vienna (ethical approval number: 2216/2020)

TRIUMPH-1 Phase 3 Trial Results Eli Lilly announced the TRIUMPH-1 results on May 21, 2026, emphasizing Retatrutide's effectiveness

Xu K, Xu Y, Brown-Jermyn D, Chen J-F, Ascherio A, Dluzen DE, et al

[DOI] [PubMed] [Google Scholar] 9

Orvosi Hetil

September 1, 2024.
